Abstract
Translation of the synergy between the Siremadlin (MDM2 inhibitor) and Trametinib (MEK inhibitor) combination observed in vitro into in vivo synergistic efficacy in melanoma requires estimation of the interaction between these molecules at the pharmacokinetic (PK) and pharmacodynamic (PD) levels. The cytotoxicity of the Siremadlin and Trametinib combination was evaluated in vitro in melanoma A375 cells with MTS and RealTime-Glo assays. Analysis of the drug combination matrix was performed using Synergy and Synergyfinder packages. Calculated drug interaction metrics showed high synergy between Siremadlin and Trametinib: 23.12%, or a 7.48% increase of combined drug efficacy (concentration-independent parameter β from Synergy package analysis and concentration-dependent δ parameter from Synergyfinder analysis, respectively). In order to select the optimal PD interaction parameter which may translate observed in vitro synergy metrics into the in vivo setting, further PK/PD studies on cancer xenograft animal models coupled with PBPK/PD modelling are needed.
Funder
Ministry of Science and Higher Education
Project “Preclinical development of an innovative anti-cancer drug using the mechanism of reactivation of p53 protein”
European Union
Subject
Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis
Reference47 articles.
1. Combination Therapy with BRAF and MEK Inhibitors for Melanoma: Latest Evidence and Place in Therapy;Eroglu;Adv. Med. Oncol.,2016
2. MDM2 Antagonists Synergize Broadly and Robustly with Compounds Targeting Fundamental Oncogenic Signaling Pathways;Saiki;Oncotarget,2014
3. Wu, C.-E., Koay, T.S., Esfandiari, A., Ho, Y.-H., Lovat, P., and Lunec, J. ATM Dependent DUSP6 Modulation of P53 Involved in Synergistic Targeting of MAPK and P53 Pathways with Trametinib and MDM2 Inhibitors in Cutaneous Melanoma. Cancers, 2018. 11.
4. Caenepeel, S., CANON, J., Hughes, P., Oliner, J.D., Rickles, R.J., and Saiki, A.Y. Combination Therapy Including an MDM2 Inhibitor and One or More Additional Pharmaceutically Active Agents for the Treatment of Cancers. U.S. Patent, 2021.
5. Resistance Acquisition to MDM2 Inhibitors;Cinatl;Biochem. Soc. Trans.,2014
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献